Section Arrow
ICCC.NASDAQ
- ImmuCell Corp
Quotes are at least 15-min delayed:2024/10/31 19:15 EDT
Last
 3.59
-0.08 (-2.18%)
Day High 
3.62 
Prev. Close
3.67 
1-M High
3.9 
Volume 
13.78K 
Bid
3.56
Ask
3.9
Day Low
3.56 
Open
3.6 
1-M Low
3.469 
Market Cap 
28.75M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.62 
20-SMA 3.63 
50-SMA 3.67 
52-W High 5.59 
52-W Low 3.34 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.52/--
Enterprise Value
43.37M
Balance Sheet
Book Value Per Share
2.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
17.47M
Operating Revenue Per Share
1.86
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.